Duffaud Florence, Le Cesne Axel
Hôpital La timone, Centre Hospitalier Universitaire de l'Assistance Publique des Hôpitaux de Marseille, 264 rue Saint Pierre, 13385, Marseille, France.
Target Oncol. 2009 Jan;4(1):45-56. doi: 10.1007/s11523-008-0101-x. Epub 2009 Jan 27.
The extraordinary success of imatinib in gastrointestinal stromal tumors (GIST) represents a model for molecularly targeted therapy for other solid tumors. Research is currently going to identify the molecular basis of mechanisms of action and drug resistance. In this article, we review recent advances in the clinical management of patients with GISTs treated with imatinib, but also of patients with dermatofibrosarcoma protuberans, chordoma, aggressive fibromatosis, and some other common solid tumors treated with this drug. We reviewed the knowledge of the molecular mechanisms that are basic to imatinib effects in these tumors.
伊马替尼在胃肠道间质瘤（GIST）治疗中取得的非凡成功为其他实体瘤的分子靶向治疗树立了典范。目前的研究旨在确定其作用机制和耐药性的分子基础。在本文中，我们回顾了伊马替尼治疗GIST患者的临床管理方面的最新进展，同时也回顾了隆突性皮肤纤维肉瘤、脊索瘤、侵袭性纤维瘤病以及其他一些使用该药物治疗的常见实体瘤患者的临床管理进展。我们还回顾了伊马替尼在这些肿瘤中发挥作用的分子机制相关知识。
